BD Boston
Date: Location: Cost:
September 4, 2018 Hilton Boston Back Bay
40 Dalton Street
Boston, MA 02115
617-326-110

Starting at $1950

 

Dress Code:
Business Attire

Register

BD BOSTON - September 4, 2018

2018 Steering Committee Members:
Kees BeenCEO, Lysosomal Therapeutics; Christopher de Souza, DirectorBroadview Ventures; Rakhshita Dhar, Business Development, Roche; John HallinanCBO, MassBio; Arthur HillerCEO, Antyllus Therapeutics; Phil McGurkBusiness Development Lead, Pfizer; Imran NasrullahDirector, Boehringer Ingelheim; Ramani VaranasiPresident & CEO, X-Biotix Therapeutics

Confirmed speakers include:
Yuval CohenCEO, Corbus Pharma; David H. DonabedianCo-Founder & CEO, Axial Biotherapeutics; Christopher GuiffreCFO & COO, Pear Therapeutics; Kate HavilandCBO, Blueprint Medicines; Jennifer KingVP Business Development, Intellia Therapeutics; Philippe Lopes-FernandesSVP, Global Head of Licensing, BD & Alliance Management, EMD Serono; Ivana Magovcevic-LiebischEVP, Chief Business Officer, Ipsen; Catherine Sohn, Chairman, BioEclipse Therapeutics; Christoph WestphalCo-Founder & Partner, Longwood Fund

Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

8:00-8:15 am

Welcome and Opening Remarks: Where Have We Been and Where Are We Going?

8:15-8:45 am

Market Outlook 2018: Drugs, Devices & Diagnostics 

8:45-9:15 am

Defining your BD Strategy vs. Opportunism - Consistent Corporate Vision
Philippe Lopes-Fernandes, SVP, Global Head of Licensing, BD & Alliance Management, EMD Serono; Susan GrafCBO, Epizyme
Moderator: Kate Haviland, CBO, Blueprint Medicines

9:15-9:45 am

The Future of Financing Models: Alternative Capital Sources
Constantine Chinoporos, CBO, Boston Pharmaceuticals; Yuval Cohen, CEO, Corbus Pharma; David Giljohann, CEO, Exicure

9:45-10:15 am

Fireside Chat
Christoph WestphalCo-Founder & Partner, Longwood Fund

10:15-10:45 am

Networking Break

10:45-11:15 am

Raising Capital  
David H. Donabedian, Co-Founder & CEO, Axial Biotherapeutics

11:15-11:45 am

Small Biotech Deal-Making and Partnering: Lessons To Be Learned
Micah Mackison, VP, Corporate Development & Strategy, Assembly Biosciences; Torsten Mummenbrauer, SVP Business Development & Licensing, Hookipa Biotech

11:45-12:15 pm

Carving up the Pie: Creative Deal Structures
Kia Motesharei, Head of BD Neurology & Immunology, EMD Serono; John D. QuiselSenior Vice President, Corporate Development, Acceleron Pharma

12:15-1:15 pm

Networking Lunch

1:15-1:45 pm

When to Think Commercial
Jean-Sebastien Cleiftie, CBO, Erytech Pharma
Moderator: Jennifer King, VP Business Development, Intellia Therapeutics

1:45-2:15 pm

Partnering: How New Modalities Impact Deal Making
Christopher Guiffre
, CFO & COO, Pear Therapeutics; Todd Smith, CEO, Novum Pharma
Moderator: David Moller, CSO, Sigilon Therapeutics

2:15-2:45 pm

BD & Academic Partnerships: New Models for Mutually Beneficial Collaborations
Moderator: James Zanewicz, Chief Business Officer, Tulane University School of Medicine

2:45-3:15 pm

Networking Break

3:15-3:45 pm

Pricing & Reimbursement Pressures on Deal Making

3:45-4:15 pm

VC Perspectives on Deal-Making in 2018

4:15-4:45 pm

Fireside Chat

4:45-5:15 pm

The Future of Deal-Making & Partnerships: 2018 and Beyond
Ivana Magovcevic-Liebisch, EVP, Chief Business Officer, Ipsen

5:15-5:25 pm

Presentation of the Deal of the Year Award

5:25-5:30 pm

Closing Remarks

5:30-6:30 pm

Cocktails and Hors d'oeuvres

Supporting Sponsors: (see all sponsors)

<